Investor profile
Laura A. Lane
Corporate VC & Vice President - Lilly Ventures (Head of Europe) at Eli Lilly and Company
Laura A. Lane is a Vice President - Lilly Ventures (Head of Europe) at Eli Lilly and Company, whose known portfolio counts 19 companies.
Is Laura A. Lane a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Sector
- AIHealthcare
Contacts
Affiliated funds' portfolios
Vice President - Lilly Ventures (Head of Europe) at Eli Lilly and Company, whose known portfolio counts 19 companies
- Haya Therapeutics
- Arda Therapeutics
- Strand Therapeutics
- TRex Bio
- Aktis Oncology
- Elektrofi
- Zephyr AI
- Ajax Therapeutics
- Artax Biopharma
- Circle Pharma
- Sunbird Bio
- Amprion
- and 7 more
Investor Profile
The listing covers sectors AI and Healthcare, and focus areas Biotech, Drug Discovery, Genomics and Machine Learning. Startups operating in these areas may find Laura A. Lane relevant.
Stage-wise, the deals at Eli Lilly and Company cluster around Growth, Late-Stage and Seed rounds.
What the affiliated firm has backed is the closest available signal on whether Laura A. Lane is worth approaching.
Colleagues at Eli Lilly and Company
Showing 20 of 23
Rebecca Canter
Executive Director - Ventures
United Kingdom
Jan Philipp Kruse
Senior Director
Berlin, Germany
Gopika Nair
Investor
San Francisco, United States
David Fink
Senior Director Transactions Venture Development
Indianapolis, United States
Emily Counceller
Investor
Indianapolis, United States
Pulkit Gupta
Executive Director, Lilly Ventures
Cambridge, United States
Bruce Konicek
Sr. Director Lilly Tech Ventures
Carmel, United States
Ekaterina Shchukina
Associate, Lilly Ventures
San Francisco, United States
Austin Bruen
Venture Capital
Indianapolis, United States
Christian Fenske
Venture Investor
Indianapolis, United States
Takao Honda
Senior Director, Lilly New Ventures, Asia
Kobe, Japan
Michelle L.
Director, Lilly Ventures
Boston, United States
Chris Tsakalakis
Group Vice President and CEO, LillyDirect
San Francisco, United States
Yi Li
Sr. Director-Medical-Accelerated R&D Leadership Program
Toronto, Canada
Andiely Lu
Vice President
Shanghai, China
M. Jaione Maiz
Senior Director
Redwood City, United States
Katie Coulter
Lilly Ventures
Boston, United States
Shah VM
Venture Capitalist
Singapore
Isabel Giangrasso
Sr. Associate - Lilly Venture Capital
United States
Tao Yu
Managing Director
Shenzhen, China
Frequently asked questions
Who is Laura A. Lane?
Laura A. Lane is a corporate venture investor based in Oxford, England, United Kingdom, listed as Vice President - Lilly Ventures (Head of Europe) at Eli Lilly and Company. The known portfolio of that firm counts 19 companies. That portfolio belongs to the firm, not to Laura A. Lane personally.
What does Laura A. Lane invest in?
Listed sectors include AI and Healthcare; listed focus areas include Biotech, Drug Discovery, Genomics and Machine Learning. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Laura A. Lane invest at?
Eli Lilly and Company appears in Growth, Late-Stage and Seed rounds across its known deals, and Laura A. Lane is listed there as Vice President - Lilly Ventures (Head of Europe). Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Laura A. Lane listed at?
Laura A. Lane is listed as Vice President - Lilly Ventures (Head of Europe) at Eli Lilly and Company. 23 other people in the database share a firm with Laura A. Lane.
How do I contact Laura A. Lane?
An email address, a phone number and a LinkedIn page are on file for Laura A. Lane. The address stays masked on this page and is readable inside RaiseHunt after you create an account.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal